Literature DB >> 15000703

The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection.

John P Moore1, Scott G Kitchen, Pavel Pugach, Jerome A Zack.   

Abstract

In this review, we will discuss what is known, what is suspected, and what still remains obscure about the central role played by coreceptor expression and usage in the transmission and pathogenic consequences of human immunodeficiency virus type 1 (HIV-1) infection. An emphasis will be on the HIV-1 phenotypic variants that are defined by their usage of the CCR5 or CXCR4 coreceptors, and how the different cellular tropism of these variants influences how and where HIV-1 replicates in vivo. We will also review what might happen when coreceptor antagonists are used clinically to treat HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15000703     DOI: 10.1089/088922204322749567

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  167 in total

1.  Persistence and emergence of X4 virus in HIV infection.

Authors:  Ariel D Weinberger; Alan S Perelson
Journal:  Math Biosci Eng       Date:  2011-04       Impact factor: 2.080

2.  Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection.

Authors:  Pierre Frange; Marie-Laure Chaix; Stéphanie Raymond; Julie Galimand; Christiane Deveau; Laurence Meyer; Cécile Goujard; Christine Rouzioux; Jacques Izopet
Journal:  J Clin Microbiol       Date:  2010-08-04       Impact factor: 5.948

3.  Can HIV be cured with stem cell therapy?

Authors:  Steven G Deeks; Joseph M McCune
Journal:  Nat Biotechnol       Date:  2010-08       Impact factor: 54.908

4.  Circulating human CD4 and CD8 T cells do not have large intracellular pools of CCR5.

Authors:  Heather A Pilch-Cooper; Scott F Sieg; Thomas J Hope; Ann Koons; Jean-Michel Escola; Robin Offord; Ronald S Veazey; Donald E Mosier; Brian Clagett; Kathy Medvik; Julie K Jadlowsky; Mark R Chance; Janna G Kiselar; James A Hoxie; Ronald G Collman; Nadeene E Riddick; Valentina Mercanti; Oliver Hartley; Michael M Lederman
Journal:  Blood       Date:  2010-11-10       Impact factor: 22.113

5.  The well-tempered SIV infection: Pathogenesis of SIV infection in natural hosts in the wild, with emphasis on virus transmission and early events post-infection that may contribute to protection from disease progression.

Authors:  Kevin Raehtz; Ivona Pandrea; Cristian Apetrei
Journal:  Infect Genet Evol       Date:  2016-07-06       Impact factor: 3.342

6.  Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.

Authors:  Masanori Baba; Hiroshi Miyake; Xin Wang; Mika Okamoto; Katsunori Takashima
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

7.  Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.

Authors:  Paul R Gorry; Rebecca L Dunfee; Megan E Mefford; Kevin Kunstman; Tom Morgan; John P Moore; John R Mascola; Kristin Agopian; Geoffrey H Holm; Andrew Mehle; Joann Taylor; Michael Farzan; Hui Wang; Philip Ellery; Samantha J Willey; Paul R Clapham; Steven M Wolinsky; Suzanne M Crowe; Dana Gabuzda
Journal:  Virology       Date:  2007-01-18       Impact factor: 3.616

8.  Novel antiretroviral agents in HIV therapy.

Authors:  Caitlin Reed; Eric S Daar
Journal:  Curr Infect Dis Rep       Date:  2006-11       Impact factor: 3.725

9.  Intrahypothalamic injection of the HIV-1 envelope glycoprotein induces fever via interaction with the chemokine system.

Authors:  Khalid Benamar; Saad Addou; Menachem Yondorf; Ellen B Geller; Toby K Eisenstein; Martin W Adler
Journal:  J Pharmacol Exp Ther       Date:  2009-11-11       Impact factor: 4.030

10.  Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition.

Authors:  Nicola Martin; Sonja Welsch; Clare Jolly; John A G Briggs; David Vaux; Quentin J Sattentau
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.